Case

A Prior PCI Is Not the Whole Story: Assessing Coronary Disease Before Surgery

When a patient has a history of PCI, the first question is not about antiplatelet therapy. The first question is whether coronary artery disease remains stable today.

Clinical scenario

A 65-year-old man is scheduled for elective laparoscopic cholecystectomy. He has a history of drug-eluting stent (DES) placement 3 years ago and is currently taking clopidogrel. He has been referred for preoperative evaluation. How do you proceed?

No current chest pain. SpO₂ 97% at rest, HR 72, BP 130/82. ECG: T-wave flattening present. Most recent cardiology visit was over 18 months ago.

When to use this page

When evaluating a patient with prior PCI and you are unsure what order to address the issues. When the reflex response is to ask about antiplatelets before evaluating the disease.

Why PCI history matters — and what it does not tell you

Key point

A prior PCI indicates the presence of coronary artery disease. It does not tell you whether that disease is stable today. The stent is evidence of a past intervention — it is not a status update.

Three years after DES placement, the coronary artery disease that prompted the PCI still exists. The stent may have addressed the culprit lesion, but the underlying disease process has not disappeared. The goal of preoperative evaluation is to determine the current state of that disease — not simply to note that PCI occurred.

Questions that determine stability

  • When was the PCI performed? DES or BMS?
  • Have there been any recurrent symptoms since PCI (chest pain, dyspnea, reduced exercise tolerance)?
  • When was the most recent cardiology review? (In this patient: >18 months ago)
  • When was the last echocardiogram? Was LVEF documented?
  • Is functional capacity adequate? Can the patient climb stairs, walk uphill, or move briskly?
  • Is the T-wave flattening on ECG new? Is there a prior ECG for comparison?

Functional capacity assessment

Key point

Absence of symptoms does not equal stability. Patients may be asymptomatic simply because their activity level has declined. Functional capacity assessment provides essential context that symptom reporting alone cannot.

When a patient reports 'no chest pain,' that does not confirm they have attempted activities that would provoke symptoms. Direct functional assessment is required. Ask specifically: can the patient climb one flight of stairs without stopping? Walk briskly on flat ground? Move quickly when needed? Avoidance of exertion may be masking reduced cardiovascular reserve.

Reviewing objective cardiac data

  • Most recent echocardiogram (LVEF, wall motion, valvular function)
  • Current ECG compared to prior baseline (the T-wave change requires context)
  • PCI report and catheterization records
  • Recent cardiology clinic notes

When recent symptoms are absent, FC is adequate, and recent objective data are stable, additional preoperative testing is often not required. However, when the most recent cardiac evaluation is over 18 months ago — as in this patient — updating that information is worth considering before surgery.

Antiplatelet therapy in context

Key point

Antiplatelet management is important — but it is one part of the overall assessment, not the whole assessment. The antiplatelet decision follows from understanding the disease, not from counting years since stent placement.

The relevant questions are: is the patient on single antiplatelet therapy or DAPT? Why is antiplatelet therapy being continued? What is the cardiologist's current management intent? Unilateral discontinuation without cardiology input carries stent thrombosis risk that cannot be estimated from stent age alone.

  • ① Confirm current antiplatelet regimen: single agent (aspirin or clopidogrel) vs DAPT
  • ② Contact the managing cardiologist to confirm the perioperative antiplatelet plan
  • ③ Do not discontinue antiplatelet therapy unilaterally before cardiology input
  • ④ Share the management plan with surgery and anesthesia before the case

How to proceed safely

  • ① Assess disease stability: symptoms, functional capacity, recent cardiology evaluation
  • ② Review objective data: echocardiogram, ECG comparison, PCI records
  • ③ Confirm antiplatelet management with cardiology
  • ④ Plan postoperative monitoring: ECG, troponin, renal function

Basis for this approach

ACC/AHA 2014 Guideline on Perioperative Cardiovascular Evaluation (antiplatelet therapy section) / JCS 2022 Guidelines on Perioperative Cardiovascular Evaluation for Non-cardiac Surgery

PCI 3 years ago, currently on clopidogrel. How do you proceed?

  1. 1.

    The antiplatelet question is important, but it follows from understanding the disease — not the other way around.

  2. 2.

    Stent age alone does not determine safety. Unilateral antiplatelet discontinuation without cardiology input carries significant stent thrombosis risk.

  3. 3.

    IHD, surgical risk, FC, and other factors can be reviewed together to see the full risk profile.

Teaching points

  • A prior PCI indicates the presence of coronary artery disease. The goal is to assess current stability — not just count years since stent placement.
  • The first question is not 'what do we do with antiplatelets?' The first question is 'how stable is the coronary disease today?'
  • Absence of symptoms does not equal stability. Functional capacity and recent cardiac evaluation provide essential context.
  • Antiplatelet therapy management is part of the overall assessment — and should be decided collaboratively with cardiology, not unilaterally.
  • The safest perioperative decisions come from understanding the disease, not just reviewing the medication list.

Next clinical question

How does the preoperative assessment change in patients with severe aortic stenosis?

Case: Severe aortic stenosis →